Study Title: A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
 

• Closed to Accrual at:
  • Michigan State University Breslin Cancer Center
  • Fred & Pamela Buffett Cancer Center (University of Nebraska)
  • Rutgers Cancer Institute of New Jersey
  • University of Wisconsin Carbone Cancer Center
  • New York University 
• Learn more:
  • clinicaltrials.gov: NCT03393845
  • Big Ten CRC News Release
• Publications and Presentations:
  • Trials in Progress: 2021 San Antonio Breast Cancer Symposium  

Study Contact: studies@hoosiercancer.org; (317) 921-2050.